Avalo Therapeutics, Inc. entered into an exchange agreement on June 11, 2026, to exchange 4,294.675 shares of Series C non-voting convertible preferred stock for an equivalent number of newly created Series C-1 non-voting convertible preferred stock. This exchange allows an investor to increase their beneficial ownership limit from 4.99% to 9.99% of the Company's common stock. Additionally, the Company amended employment agreements for CEO Garry A. Neil, CFO Christopher Sullivan, M.D., CMO Mittie Doyle, and CBO Taylor Boyd to modify severance and change in control benefits. Avalo Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.
